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Short-acting b2-adrenergic receptor agonists are commonly used bronchodilators for symptom relief in asthmatics. The aim of
this study was to test whether genetic variants in PDE4D gene, a key regulator of b2-adrenoceptor-induced cAMP turnover in
airway smooth muscle cells, aﬀect the response to short-acting b2-agonists. Bronchodilator responsiveness was assessed in 133
asthmatic children by % change in baseline forced expiratory volume in one second (FEV1) after administration of albuterol. The
analyses were performed in patients with airway obstruction (FEV1/FVC ratio below 90%, n = 93). FEV1 % change adjusted for
baseline FEV1 values was signiﬁcantly diﬀerent between genotypes of rs1544791 G/A polymorphism (P = 0.006) and −1345 C/T
(rs1504982) promoter variation (P = 0.03). The association remained signiﬁcant with inclusion of age, sex, atopy, and controller
medication into multivariate model (P = 0.004 and P = 0.02, resp.). Our work identiﬁes new genetic variants implicated in
modulation of asthma treatment, one of them (rs1544791) previously associated with asthma phenotype.
1.Introduction
Asthma (MIM 600807) is a common chronic respiratory dis-
ease resulting from the complex interaction of genetics and
environmentalfactors[1].Short-acting b2-adrenergic recep-
tor agonists are commonly used bronchodilators for symp-
tom relief in asthmatics. Activated b2-adrenergic receptor
(ADRB2) stimulates adenylyl cyclase leading to increased
cyclic adenosine monophosphate (cAMP) level. A primary
function of cAMP is to activate protein kinase A (PKA),
which in turn activates myosin light chain phosphatase,
reducing phosphorylation and generating relaxation [2].
cAMP-activated PKA also activates and phosphorylates
phosphodiesterase 4 (PDE4) isoforms which then degrade
cAMP providing thus a pivotal acute feedback mechanism
[2–4].
PDE enzymes, ubiquitously distributed in mammalian
tissues, are essential to control numerous physiological pro-
cesses. PDEs are encoded by 11 gene families, each encom-
passing 1 to 4 subfamilies of distinct genes [5, 6]. The
PDE4 family has gained interest in view of their involvement
in the regulation of processes such as inﬂammation and
cognition [3, 7]. Four genes (4A–D) encode a large number
of PDE4 isoforms through activation of diﬀerent promoters
or alternative splicing [3, 7]. The dominant PDE4 type
expressed in airway smooth muscle cells is PDE4D [8–
10]. PDE4D encode a variety of long and short isoforms
which are summarized in Figure 1.L o n gPDE4D5 isoform
was shown to be a key regulator of b2-adrenoceptor-in-
duced cAMP turnover in human airway smooth muscle
cells [11]. The promoter of PDE4D5 isoform contains
a cAMP response element [8]. Chronic elevation of cAMP2 Mediators of Inﬂammation
D7a D7bD7c D4 D5 D3 D11 D8 D9 Exons 2 3 45 , D6 D1 Exons 6–15
rs1544791 rs1504982 rs10940648 rs829259
59820000 58301000
3UTR
D2 D10
COPD BMD Stroke
Figure 1: Schematic representation of PDE4D gene. Modiﬁed from Houslay [7]. Chromosomal positions are marked at the beginning and
at the end of the gene. The orientation of the gene is inversed since PDE4D is encoded on the reverse strand. Common exons are represented
by black squares. There are long, short, or supershortsplice variants depending on the location of their uniqueN-terminalregions (D1–D11,
grey squares). For simplicity and due to the large size of the gene (over 1.5Mb), the exon positions are not to scale. Four SNPs used in the
present studies are shown, and these signiﬁcantly associated with b2-response are underlined. Position of SNPs associated with stroke [15],
bonemineraldensity(BMD)[16]andchronicobstructivepulmonarydisease(COPD)[17]isindicated.rs1544791waspreviouslyassociated
with asthma [18].
could therefore lead to desensitization of the receptor to
b2-agonists following long-term exposure. This diﬀers from
the acute transient desensitization of the receptor caused by
PKA phosphorylation and activation or by agonist-triggered
b-arrestin-mediated recruitment to the b2-adrenoreceptor
[12, 13]. Experiments using knockout mice for PDE4D gene
further supported PDE4D role in a regulation of airway
smooth muscles contractility [9, 14].
It is thus not surprising that recent genome-wide associ-
ationstudy(GWAS)forasthmaidentiﬁed PDE4Dasahighly
plausible candidate gene [18]. PDE4D was also associated
with mineral bone density [16], chronic obstructive pul-
monary disease (COPD) in Japanese population [17], and
stroke [15, 19]. PDE4D associations with diverse phenotypes
are most likely due to its multiple splicing forms with exons
scattered over 1.5Mb, each regulated in a tissue-and-cell
speciﬁcmannerandinvolvedinmultiplesignallingprocesses
[3, 7, 20].
As the role of PDE4 enzymes was discovered, the interest
in controlling their activity was apparent, as summarized in
several reviews [2, 20–23]. PDE4 inhibitors have been also
viewed as a promising therapy for the treatment of inﬂam-
matory airway disorders [24]. The potentially beneﬁcial
action of PDE4 inhibitors has been successfully translated
in clinical trials for COPD treatment [22, 25, 26], and their
eﬃcacy for asthma control is presently under investigation
[27].
No data are yet available on the involvement of this gene
in the response to drugs used in asthma treatment. The aim
of this study was to test the genetic variants in PDE4D gene
as potential predictive factor of the response to a single dose
of short-acting b2-agonist.
2. Patientsand Methods
2.1. Patients. Patients (n = 133) were recruited from the
asthma and outpatient pulmonary clinics at Sainte-Justine
Hospital between March 2007 and September 2010. Subjects
were eligible if they were Caucasians, aged 5 to 18 years, able
to perform an appropriate spirometric maneuver under the
supervision of technicians speciﬁcally trained in pulmonary
function testing of children [28], and meeting standard
criteria for a diagnosis of asthma [29]. Subjects were eligible
for the recruitment irrespectively of the type of maintenance
therapy (inhaled corticosteroids, ICS, or leukotriene modi-
ﬁers) and irrespectively of disease control and severity. Atopy
was deﬁned as presence of physician-diagnosed eczema
and/or serum food-speciﬁc IgE and/or positive skin test for 1
or more aeroallergens or food antigens [30]. Exclusion crite-
ria were as follows: use of long-acting bronchodilators in the
last month, prematurity, a history of signiﬁcant pulmonary
disease other than asthma, and known immunodeﬁciencies.
ThestudyprotocolwasreviewedandapprovedbytheSainte-
Justine Hospital Ethics Committee, and informed consent
was signed by each patient’s parent.
Toassessbronchodilatorresponsiveness, fourinhalations
of albuterol were administered via metered dose inhaler
(100μg/inhalation) with valved holding chamber and
mouthpiece (Aerochamber; Invacare Corp, Elyria, Ohio,
USA). Spirometry was performed before (pre) and 15min
after (post) receiving albuterol sulfate in accordance with
the American Thoracic Society guidelines [28]. Short-acting
bronchodilators were withheld 6 hours prior to baseline
spirometry. Responsiveness to albuterol was reported as the
percent change in forced expiratory volume in one second
(FEV1) after albuterol administration: 100 × ((FEV1(post) −
FEV1(pre))/FEV1(pre)). The equations proposed by Polgar
and Promadath [31] were selected for the calculation of
predicted and reference values.
2.2. Genotyping. DNA was extracted from saliva using Ora-
gen kit according to manufacturer (DNA Genotek, http://
www.dnagenotek.com). Four SNPs in PDE4D gene were
selected for the analysis. Two polymorphisms, located at
positions −1345(rs1504982)and −984(rs10940648)relative
totheﬁrstnucleotideofPDE4D5mRNAisoform(AF12073),
were the only SNPs available at NCBI data base that reside
in the 2kb region preceding PDE4D5 transcription start site.
Two other PDE4D polymorphisms were selected based on
published data: rs1544791, located in the intron 2 of theMediators of Inﬂammation 3
Table 1: Primers used for ampliﬁcation and genotyping of PDE4D polymorphisms.
SNP ID Position PCR primers ASO primers
rs1544791 Intron 2 GAAGCATGTTGCACATAAACTG, ATGTGGCA/GTTATTTGC
TCTCTTCTACTCTATGGGCTTTCTG
rs1504982 −1345 GGGAGCTACAAAATGCATCC, ATTCCTTGC/TCTTTTAAA
CAAGTGGTTGACCCTGTCCT
rs10940648 −984 CGTGATTTCCTTTATTGCCTTT, AGTAAAAAT/CGTTGTAAC
TTCCCTATGCAAAGGTTTGAG
rs829259 3 UTR TTGTCCCTGAGTGAAGTCTAGAAA, TCCCTACT/ACTTAGTAT
CCCTTTCAGGTCTGGATTTG
rs1544791 is located in intron 2 of PDE4D7 isoform; positions of rs1504982 and rs10940648 refer to the start of PDE4D5 mRNA (AF012073) and, rs829259 is
located in 3 UTR, common to all splice variants.
longest PDE4D7 isoform (NM 001165899.1), was a top-
ranking SNP in the GWAS of asthma [18] and the other,
rs829259, located in 3 UTR of all PDE4D isoforms, was
reported in association with the COPD in adults [17].
AllDNAsegmentscontainingthepolymorphicsiteswere
ampliﬁed by PCR in a total volume of 20ul using 15ng
of genomic DNA, 0.4μM of each primer, 140μMd N T P s ,
10mM Tris-HCl (pH 8.3), 2.3mM MgCl2,5 0m MK C l ,a n d
0.4U of Platinum Taq polymerase (Invitrogen). Ampliﬁca-
tion was performed for 37 cycles composed of 30s at 94◦C,
30s at 57◦C, and 30s at 72◦C, following initial denaturation
of 3min at 95◦C. Genotyping was performed by allele-
speciﬁc oligonucleotide (ASO) hybridization as described
previously [32]. The sequence of primers used for PCR and
ASO is provided in Table 1.
2.3. Statistical Analysis. The % change in FEV1 was ana-
lyzed by analysis of covariance (ANCOVA). Genotype was
included in the model as ﬁxed factor, and the baseline
FEV1% predicted value was included as continuous covari-
ate. The analyses were restricted to patients having airway
obstruction, for example, baseline FEV1/FVC (FVC—forced
vital capacity) ratio lower than 90% [33, 34] (see Table 2
for patients characteristics). Hierarchical multivariate lin-
ear regression was used to assess the association between
genotypes of rs1544791 and rs1504982 with the inclusion of
additional covariates (age, sex, atopy, and use or not of ICS
and leukotriene modiﬁers). The analyses were performed by
SPSS (Version 17.0).
3. Results andDiscussion
Details of patients’ characteristics are provided in Table 2.
Asthma severity of patients recruited in our study is com-
parable to that observed in the Childhood Asthma Manage-
ment Program (CAMP) and the Leukotriene Modiﬁer or
Corticosteroid or Corticosteroid Salmeterol trial (LOCCS)
populations [35] used in a number of pharmacogenetic
studies. Table 3 presents mean % FEV1 change according
to genotypes in PDE4D gene. Signiﬁcant diﬀerences were
obtained for PDE4D5 promoter −1345 (rs1504982, P = 0.03)
and for rs1544791 polymorphisms (P = 0.006). The mean
%F E V 1 change ± SE for rs1504982 C carriers was 7.1 ±
0.7 versus 10.3 ± 1.2 in noncarriers, and for rs1544791 G
Table 2: Patients’ characteristics.
Characteristic∗ Total (n = 133) Total (n = 93)
Age, years 9.8 (±0.3) 10.3 (±0.3)
Males, n (%) 73 (54.9) 55 (59.1)
Females, n (%) 60 (45.1) 38 (40.9)
Atopy∗∗, n (%) 100 (75.2) 73 (78.5)
Parental smoking, n (%) 36 (27.1) 27 (29.0)
Regular ICS use, n (%) 68 (51.1) 48 (51.6)
Leukotriene modiﬁer use, n (%) 28 (21.1) 21 (22.6)
Baseline FVC, % predicted 106.8 (±1.1) 108.6 (±1.3)
Baseline FEV1, % predicted 96.9 (±1.2) 94.0 (±1.2)
Baseline FEV1/FVC ratio 84.5 (±0.8) 80.5 (±0.7)
∗Patients’ characteristics are given as number (%) or mean ± SE for entire
group of patients (n = 133) or for patients with FEV1/FVC ratio below 90%
(n = 93) to which the genotype analysis was restricted to; ∗∗presence of
physician-diagnosed eczema, food-speciﬁc IgE, and/or positive skin test for
1 or more aeroallergens or food allergens [30]; ICS: inhaled corticosteroids,
FVC: forced vital capacity, FEV1: forced expiratory volume in one second.
carriers, the mean % FEV1 change ± SE was 7.4 ± 0.7 as
compared to 13.7 ± 2.1 in individuals without this allele.
The association remained signiﬁcant for both SNPs with
inclusion of age, sex, atopy, and controller medication into
the multivariate model (P = 0.02 and P = 0.004, resp.).
The recent association of PDE4D to asthma phenotype
[18], as well as its known function, makes PDE4D an
excellentcandidategenefortheassociationwiththeoutcome
of asthma treatment. PDE4D is a well-established regu-
lator of airway smooth muscles contractility [9, 14]a n d
plays a key role in ADRB2-induced cAMP regulation
[11]. Study conducted in vitro demonstrated that a single
nucleotide substitution in one of cAMP-responsive elements
in PDE4D5 promoter created by site-directed mutagenesis,
causes cAMP-driven upregulation of PDE4D5 expression
and functional activity in human airway smooth muscle cells
[8]. Based on the publicly available data, it does not seem
that there is a naturally occurring genetic variant in PDE4D5
cAMP-responsive elements. Among SNPs analyzed here,
−1345 variation of the PDE4D5 promoter was associated
with the change in FEV1 following a single dose of short-
acting b2-agonist. The change in FEV1 was also signiﬁcantly
associated with rs1544791, the top ranking SNP in GWAS
study of asthma susceptibility [18]. The same G asthma4 Mediators of Inﬂammation
Table 3:FEV1%changefollowingadministrationofalbuterolacco-
rding to PDE4D genotypes.
SNP/genotypes N %F E V 1 change (mean ± SE)∗∗ P∗∗∗
rs1544791 intron2
AA 8 13.7 (±2.1) 0.01
AG 34 6.6 (±1.0)
GG 51 7.9 (±0.8)
GG+GA versusAA 7.4 ±0.7 versus13.7 ±2.1 0.006
rs1504982 (−1345∗)
CC 22 7.0 (±1.3)
0.08 CT 46 7.1 (±0.9)
TT 25 10.3 (±1.2)
CC+CTversus TT 7.1 ±0.7 versus10.3 ±1.2 0.03
rs10940648 (−984∗)
CC 6 8.2 (±2.6)
0.4 TC 28 6.6 (±1.2)
TT 59 8.5 (±0.8)
rs829259
AA 13 8.5 (±1.7)
0.1 AT 45 6.6 (±0.9)
TT 35 9.5 (±1.1)
rs1544791 is located in intron 2 of PDE4D7 isoform; ∗positions of
rs1504982 and rs10940648 refer to the start of PDE4D5 mRNA (AF012073),
and rs829259 is located in 3 UTR common to all splice variants; ∗∗mean
values adjusted for baseline FEV1; ∗∗∗P derived from ANCOVA.
predisposing allele was associated in our study with the poor
treatment outcome.
Schematic representation of PDE4D gene structure and
r e l a t i o nt oP D E 4 Di s o f o r m si sg i v e ni nFigure 1.S N P st e s t e d
within this study are depicted as well as those associated with
variety of phenotypes reported by others [15–17]. Each of
thephenotypesassociatedwithPDE4Dgene(stroke,asthma,
BMD, and COPD) maps to diﬀerent linkage disequilibrium
(LD) blocks. The same is true for the SNPs signiﬁcantly
associated with b2-agonist response in this study. The
SNP rs1544791 is located within 181kb intron 2 of the
longest isoform (PDE4D7, NM 001165899.1). This SNP
resides within 75kb long LD block and is separated by
374kb from PDE4D5 transcription start. Despite its distant
location, it could act as a remote cis-acting element. Indeed,
functional-SNP database (F-SNP) integrating information
from 16 bioinformatics tools [36] predicts that it might
be a transcription regulator. We further assessed rs1544791
in allelic expression dataset generated in HapMap lym-
phoblastoid (CEU) cell lines of European ancestry [37]
where allelic diﬀerences within individual were renormal-
ized as recently described [38]. Population diﬀerences for
allelic expression of uc010iwj.1 isoform (also corresponding
to the ﬁrst few exons unique to the longest PDE4D7
isoform NM 001165899.1 [7]) were signiﬁcantly associated
(P = 0.005) with rs1544791 genotype. SNP −1345 is also
recognizedastranscriptionregulatorinF-SNPdatabase[36]
and in UCSC browser (http://genome.ucsc.edu).
In the analysis, we used % FEV1 change as a continuous
variable with the correction for baseline FEV1% predicted
values rather than categorical phenotype of responders and
nonresponders based on a % FEV1 change above or below a
given predeﬁned value. The reason for this was a strong pos-
itive correlation between poor response to the administered
albuterol and high baseline FEV1% predicted values. Since
about50%ofourpatients wereonregularICSand20%were
onleukotrienemodiﬁers,itisreasonabletoassumethatprior
treatment with these drugs had improved lung function in
a proportion of our study subjects, therefore reducing the
magnitude of the response to albuterol. Because of ethical
considerations, we did not withdraw anti-inﬂammatory
treatment prior to assessment, but we therefore restricted
our analysis to the patients with airway obstruction. Since
airway obstruction is deﬁned by a reduced FEV1/FVC ratio
[34] which normally reaches a value of 0.9 in children
[33], we limited our analysis to patients with FEV1/FVC
ratio lower than that threshold. An alternative strategy
would have been to recruit new asthma patients prior to
initiationofanyasthmacontrollertherapy.However,onsetof
childhood asthma usually occurs early during the preschool
age and valuable spirometric data cannot be obtained in
preschoolers.Amulticenterstudywouldhavebeennecessary
in order to recruit the appropriate numbers of patients.
4. Conclusions
This study demonstrates the ﬁrst attempt to explore the
association of PDE4D genetic variations and response to
asthma b2-agonists treatment in Caucasian children. Results
obtained are not necessarily applicable to other populations
a sf r e q u e n c yo ft e s t e dp o l y m o r p h i s m sa n dL Ds t r u c t u r e
diﬀer [18]. If conﬁrmed in a larger study, this ﬁnding will
build upon existing knowledge in asthma pharmacogenetics
ultimately assisting personalized patient treatment.
Funding
The work was supported by a Grant from the Canadian
Institutes of Health Research (MOP-81154); M. Krajinvoic is
a scholar of the Fonds de la Recherche en Sant´ ed uQ u ´ ebec.
T. Pastinen is supported by CIHR and holds a CRC (tier 2).
Acknowledgments
The authors are thankful to all the patients and their parents
who consented to participate in this study. They thank Dr.
Chauhan Bhupendrasinh for the critical reading of the
manuscript.
References
[1] S. T. Weiss, “Gene by environment interaction and asthma,”
Clinical and Experimental Allergy, vol. 29, supplement 2, pp.
96–98, 1999.
[2] M. D. Houslay, “Underpinning compartmentalised cAMP
signalling through targeted cAMP breakdown,” Trends in Bio-
chemical Sciences, vol. 35, no. 2, pp. 91–100, 2011.Mediators of Inﬂammation 5
[ 3 ]M .D .H o u s l a ya n dD .R .A d a m s ,“ P D E 4c A M Pp h o s p h o d i -
esterases: modular enzymes that orchestrate signalling cross-
talk, desensitization and compartmentalization,” Biochemical
Journal, vol. 370, part 1, pp. 1–18, 2003.
[4] S. J. MacKenzie, G. S. Baillie, I. McPhee et al., “Long PDE4
cAMP speciﬁc phosphodiesterases are activated by protein
kinase A-mediated phosphorylation of a single serine residue
in Upstream Conserved Region 1 (UCR1),” British Journal of
Pharmacology, vol. 136, no. 3, pp. 421–433, 2002.
[5] M. Conti and S. L. Jin, “The molecular biology of cyclic
nucleotide phosphodiesterases,” Progress in Nucleic Acid Re-
search and Molecular Biology, vol. 63, pp. 1–38, 1999.
[6] M. D. Houslay, “PDE4 cAMP-speciﬁc phosphodiesterases,”
Progress in Nucleic Acid Research and Molecular Biology, vol.
69, pp. 249–315, 2001.
[7] M.D.Houslay,“Thelongandshortofvascularsmoothmuscle
phosphodiesterase-4 as a putative therapeutic target,” Molecu-
lar Pharmacology, vol. 68, no. 3, pp. 563–567, 2005.
[8] I. R. Le Jeune, M. Shepherd, G. van Heeke, M. D. Houslay,
and I. P. Hall, “Cyclic AMP-dependent transcriptional up-
regulationofphosphodiesterase4D5inhumanairwaysmooth
muscle cells: identiﬁcation and characterization of a novel
PDE4D5 promoter,” Journal of Biological Chemistry, vol. 277,
no. 39, pp. 35980–35989, 2002.
[9] C. M´ ehats, S. L. Jin, J. Wahlstrom, E. Law, D. T. Umetsu, and
M. Conti, “PDE4D plays a critical role in the control of airway
smooth muscle contraction,” FASEB Journal, vol. 17, no. 13,
pp. 1831–1841, 2003.
[ 1 0 ] T .J .T o r p h y ,B .J .U n d e m ,L .B .C i e s l i n s k i ,M .A .L u t t m a n n ,M .
L. Reeves, and D. W. Hay, “Identiﬁcation, characterization
and functional role of phosphodiesterase isozymes in human
airway smooth muscle,” Journal of Pharmacology and Experi-
mental Therapeutics, vol. 265, no. 3, pp. 1213–1223, 1993.
[11] C. K. Billington, I. R. Le Jeune, K. W. Young, and I. P. Hall, “A
major functional role for phosphodiesterase 4D5 in human
airway smooth muscle cells,” American Journal of Respiratory
Cell and Molecular Biology, vol. 38, no. 1, pp. 1–7, 2008.
[12] G. S. Baillie, A. Sood, I. McPhee et al., “β-arrestin-mediated
PDE4 cAMP phosphodiesterase recruitment regulates β-adre-
noceptor switching from Gs to Gi,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 100,
no. 3, pp. 940–945, 2003.
[13] M. J. Lynch, G. S. Baillie, A. Mohamed et al., “RNA silencing
identiﬁes PDE4D5 as the functionally relevant cAMP phos-
phodiesterase interacting with βarrestin to control the protein
kinase A/AKAP79-mediated switching of the β2-adrenergic
receptor to activation of ERK in HEK293B2 cells,” Journal of
Biological Chemistry, vol. 280, no. 39, pp. 33178–33189, 2005.
[14] G. Hansen, S. L. Jin, D. T. Umetsu, and M. Conti, “Absence of
muscarinic cholinergic airway responses in mice deﬁcient in
the cyclic nucleotide phosphodiesterase PDE4D,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 97, no. 12, pp. 6751–6756, 2000.
[15] S. Gretarsdottir, G. Thorleifsson, S. T. Reynisdottir et al., “The
gene encoding phosphodiesterase 4D confers risk of ischemic
stroke,” Nature Genetics, vol. 35, no. 2, pp. 131–138, 2003.
[16] R. H. Reneland, S. Mah, S. Kammerer et al., “Association bet-
ween a variation in the phosphodiesterase 4D gene and bone
mineral density,” BMC Medical Genetics, vol. 6, article 9, 2005.
[17] S. Homma, T. Sakamoto, A. E. Hegab et al., “Association of
phosphodiesterase 4D gene polymorphisms with chronic obs-
tructivepulmonarydisease:relationshiptointerleukin13gene
polymorphism,” International Journal of Molecular Medicine,
vol. 18, no. 5, pp. 933–939, 2006.
[18] B. E. Himes, G. M. Hunninghake, J. W. Baurley et al., “Ge-
nome-wide association analysis identiﬁes PDE4D as an
asthma-susceptibility gene,” American Journal of Human
Genetics, vol. 84, no. 5, pp. 581–593, 2009.
[19] A. Munshi and S. Kaul, “Stroke genetics—focus on PDE4D
gene,” International Journal of Stroke, vol. 3, no. 3, pp. 188–
192, 2008.
[20] M. D. Houslay, P. Schafer, and K. Y. Zhang, “Keynote review:
phosphodiesterase-4 as a therapeutic target,” Drug Discovery
Today, vol. 10, no. 22, pp. 1503–1519, 2005.
[21] R.E.Weishaar,M.H.Cain,andJ.A.Bristol,“Anewgeneration
of phosphodiesterase inhibitors: multiple molecular forms
of phosphodiesterase and the potential for drug selectivity,”
Journal of Medicinal Chemistry, vol. 28, no. 5, pp. 537–545,
1985.
[22] D. Spina, “PDE4 inhibitors: current status,” British Journal of
Pharmacology, vol. 155, no. 3, pp. 308–315, 2008.
[23] B. J. Lipworth, “Phosphodiesterase-4 inhibitors for asthma
and chronic obstructive pulmonary disease,” Lancet, vol. 365,
no. 9454, pp. 167–175, 2005.
[24] R. W. Chapman, A. House, J. Richard et al., “Pharmacology of
a potent and selective inhibitor of PDE4 for inhaled adminis-
tration,” European Journal of Pharmacology, vol. 643, no. 2-3,
pp. 274–281, 2010.
[25] J. Chong, P. Poole, B. Leung, and P. N. Black, “Phosphod-
iesterase 4 inhibitors for chronic obstructive pulmonary dis-
ease,” Cochrane Database of Systematic Reviews, vol. 5, Article
ID CD002309, 2011.
[26] A. Hatzelmann, E. J. Morcillo, G. Lungarella et al., “The pre-
clinical pharmacology of roﬂumilast - A selective, oral phos-
phodiesterase 4 inhibitor in development for chronic obstruc-
tive pulmonary disease,” Pulmonary Pharmacology and Thera-
peutics, vol. 23, no. 4, pp. 235–256, 2010.
[27] A. T. Nials, C. J. Tralau-Stewart, M. H. Gascoigne, D. I. Ball,
L. E. Ranshaw, and R. G. Knowles, “In vivo characterization
of GSK256066, a high-aﬃnity inhaled phosphodiesterase 4
inhibitor,” Journal of Pharmacology and Experimental Thera-
peutics, vol. 337, no. 1, pp. 137–144, 2011.
[28] M. R. Miller, J. Hankinson, V. Brusasco et al., “Standardisation
ofspirometry,”EuropeanRespiratoryJournal,v ol.26,no .2,pp .
319–338, 2005.
[29] National Asthma Education and Prevention Program, “Expert
Panel report 3: guidelines for the diagnosis and management
of asthma,” U.S. Department of Health and Humane Services,
NationalInstitutesofHealth,NationalHeart,Lung,andBlood
Institute, 2007.
[30] L. B. Bacharier, A. Boner, K. H. Carlsen et al., “Diagnosis and
treatment of asthma in childhood: a PRACTALL consensus
report,” Allergy, vol. 63, no. 1, pp. 5–34, 2008.
[31] G. Polgar and V. Promadath, Pulmonary Function Testing in
Children: Techniques and Standards, WB Saunders, Philadel-
phia, Pa, USA, 1974.
[32] S.BourgeoisandD.Labuda,“Dynamicallele-speciﬁcoligonu-
cleotide hybridization on solid support,” Analytical Biochem-
istry, vol. 324, no. 2, pp. 309–311, 2004.
[33] M. D. Lougheed, C. Lemiere, S. D. Dell et al., “Canadian Tho-
racic Society Asthma Committee commentary on long-acting
beta-2 agonist use for asthma in Canada,” Canadian Respira-
tory Journal, vol. 17, no. 1, pp. 15–24, 2010.
[34] R.Pellegrino,G.Viegi,V.Brusascoetal.,“Interpretativestrate-
gies for lung function tests,” European Respiratory Journal, vol.
26, no. 5, pp. 948–968, 2005.
[35] A.A.Litonjua,J.Lasky-Su,K.Schneiteretal.,“ARG1isanovel
bronchodilator response gene: screening and replication in6 Mediators of Inﬂammation
four asthma cohorts,” American Journal of Respiratory and
Critical Care Medicine, vol. 178, no. 7, pp. 688–694, 2008.
[36] P. H. Lee and H. Shatkay, “F-SNP: computationally predicted
functional SNPs for disease association studies,” Nucleic Acids
Research, vol. 36, no. 1, pp. D820–D824, 2008.
[37] B. Ge, D. K. Pokholok, T. Kwan et al., “Global patterns of
cis variation in human cells revealed by high-density allelic
expressionanalysis,”Nature Genetics,vol.41,no.11,pp.1216–
1222, 2009.
[38] E. Grundberg, V. Adoue, T. Kwan et al., “Global analysis of
theimpact ofenvironmental perturbationoncis-regulationof
gene expression,” PLoS Genetics, vol. 7, no. 1, Article ID
e1001279, 2011.